Neurodevelopmental and Epilepsy Phenotypes in Individuals With Missense Variants in the Voltage-Sensing and Pore Domains of .

Background And Objectives: encodes the voltage-gated potassium channel EAG2/Kv10.2. We aimed to delineate the neurodevelopmental and epilepsy phenotypic spectrum associated with de novo variants.

High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system.

Genistein (4,5,7-trihydroexyisoflavone), a soy derived isoflavone, has been proposed as a substrate reduction therapy in patients with mucopolysaccharidoses (MPS) disorders with central nervous system involvement based on studies in cultured fibroblasts demonstrating that this agent inhibits glycosaminoglycan synthesis. Several studies have reported treatment of MPS III patients with low dose genistein (5-15mg/kg/day) with no serious adverse effects and variable neurocognitive outcomes. Mice with MPS IIIB treated with high dose (160mg/kg/day) genistein exhibited a significant decrease in heparan sulfate accumulation and neuroinflammation in the brain and improvement of the behavioral phenotype.

CDKL5 and ARX mutations in males with early-onset epilepsy.

Mutations in CDKL5 and ARX are known causes of early-onset epilepsy and severe developmental delay in males and females. Although numerous males with ARX mutations associated with various phenotypes have been reported in the literature, the majority of CDKL5 mutations have been identified in females with a phenotype characterized by early-onset epilepsy, severe global developmental delay, absent speech, and stereotypic hand movements. To date, only 10 males with CDKL5 mutations have been reported.

Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses.

The transition to home infusion therapy is described in 11 patients with mucopolysaccharide (MPS) disorders initially treated with enzyme replacement therapy (ERT) in an out-patient infusion center. Home therapy was well tolerated with no infusion-related reactions (IRR) occurring in 671 patient-weeks of treatment. In addition, compliance with the weekly treatment regimen was improved in patients on home therapy.